|  |  |  |
| --- | --- | --- |
|  | **SupplySide West 2019 Lecture Schedule:** | |
|  |  |  |
| *Each lecture should be approximately 30 minutes each plus time for Q&A /networking afterward.* | | |
| *Companies can make full use of the 40minutes allotted* | | |
|  |  |  |
|  | **DAY 1 – Thursday, October 17th** | **DAY 2 – Friday, October 18th** |
|  | *Expo Hall Open 10:00-5:30* | *Expo Hall Open 10:00-5:00* |
|  |  |  |
| **10:30-11:10** | **Opening** | **Opening** |
|  | **1- KGK Science**  Title: Impact of a Finalized NDI Guidance to Probiotics  Abstract: The most pressing questions for the supplement industry in 2020 will revolve around the anticipated finalization of FDA’s New Dietary Ingredient (NDI) guidance for industry. When will it be finalized? How will it impact probiotics? Will FDA hold to safety at the strain level? These are all valid questions over a document and process that started with the passage of FSMA nearly a decade ago on January 4, 2011. FDA will have their own questions once it is released in final form. Will it change submission rates of NDI notifications? What enforcement strategies are available to compel compliance to FDA’s NDI notification requirement? While some companies have been preparing nearly a decade for this day to come, the final NDI guidance will be a big pill to swallow for others.  Topics  • Safety assessments for live microbial ingredients.  • Identity considerations.  • What to expect in the NDI Finalized Guidance for Industry.  Presenter: Dr. Corey Hilmas, MD, Ph.D.  Job Title: Chief Regulatory Officer, KGK Science  Bio: Dr. Corey Hilmas is a respected scientist and former federal regulator with many years of US federal service. He is a recipient of the FDA Commissioner’s Award of Merit for trial work on behalf of the US government and an industry-recognized regulatory expert with an intimate knowledge of the dietary supplement industry and US FDA. He was a principal investigator for preclinical safety and efficacy assessment. Dr. Hilmas oversaw the development and implementation of all scientific, regulatory, educational, and compliance programs in his previous employment, writing over 65 comments to 10 federal and state agencies. Dr. Hilmas also worked on the Supplement Safety & Compliance Initiative (SSCI), assisting with drafting technical benchmarking guidance and governance documents to establish the initial groundwork of the organization. Dr. Hilmas also acted as the Executive Director for the Natural Products Foundation, where he provided regulatory solutions, wrote warning letters to identify non-compliant products for federal regulators, and tested random products for GMP compliance through the NPF TruLabel Program.  Company Profile: Short company profile: KGK Science is a leading full-service contract research organization and regulatory consulting firm in the nutraceutical & cannabinoid industries specializing in the creation of client-specific approaches and tailor-made regulatory solutions for ensuring product and ingredient compliance. For over 23 years, KGK has successfully helped companies design cost-effective clinical studies to meet FDA/FTC, Health Canada and EFSA regulations, aiding claims substantiation and impacting product marketing | **9- BioCC LLC**  Title: *L. plantarum* INDUCIA® as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against *Clostridium difficile* (USA patent US10272122)  Abstract: Novel multifunctional probiotic Lactobacillus plantarum INDUCIA® maintains cardiovascular health by reduction of LDL-cholesterol levels and by preventing formation of oxidized low-density lipoprotein (oxLDL). Elevated LDL-cholesterol levels and impaired bioquality of LDL particles are important contributors in the pathogenesis of atherosclerotic cardiovascular diseases. L. plantarum INDUCIA® has shown to reduce the colonization of C. difficile in the gut. Combination of xylitol with L. plantarum INDUCIA® suppresses the germination of spores and outgrowth into vegetative toxin producing cells of C. difficile. Putative therapeutical approach includes usage of the synbiotic during antimicrobial therapy for prevention of CDI and its potential to reduce recurrences of CDI.  Topics  • *Lactobacillus plantarum* INDUCIA® helps to maintain cardiovascular health.  • Proven by clinical trials - reduces levels of important risk factors of cardiovascular diseases: cholesterol and oxidized LDL.  • Antagonistic activity of L. plantarum INDUCIA® against vegetative cells of *C. difficile*.  Presenter 1: Dr Kersti Ehrlich-Peets  Job Title 1: Senior Researcher  Bio 1: I am Dr. Kersti Ehrlich-Peets and I currently work at BioCC LLC as a Senior Researcher and an expert of biochemistry. I am also employed by the Department of Biochemistry, Faculty of Medicine, University of Tartu where my main task is teaching biochemistry to medical students. I have defended doctoral thesis on 2009 in the field of design, synthesis and primary testing of novel antioxidative peptides, for a degree of *Doctor medicinae* (Dr.Med.). My research interests at the moment are related to health improving qualities of probiotic bacteria. More thoroughly I have researched proteolytic properties of *Lactobacillus* in milk products with purpose of finding bioactive compounds, especially with focus on cardiovascular health. During my career as a researcher I have studied antioxidative effects of glutathione analogues, oxidative DNA damages and the safety of plastic food packages and also participated in the creation of accredited laboratory of chemistry in BioCC LLC.  Presenter 2: Liina Kuus, M.Sc. student  Job Title 2: Manager of Production and Clinical Trials  Bio 2: I am Liina Kuus and I currently work at BioCC LLC as a manager of production and clinical trials. Currently my research interest is development of bacteria strains into multipotent probiotics that could prevent different health problems. Probiotic development process comprises of in vitro safety, in vivo safety, tolerability and efficacy clinical trials.  Company Profile: BioCC LLC is a bioscience company focused on comprehensive and high-quality R&D. Portfolio of BioCC contains a range of probiotic products comprising of clinically validated patented multipotent anti-inflammatory, antioxidative Lactobacillus spp strains (TENSIA®, INDUCIA® and MCC1®) under the Nordwise® brand for cardiovascular health (lowering blood pressure, cholesterol levels, reducing oxidative stress etc.), supporting gut health and immune system. |
| **11:10-11:20** | **Break** | **Break** |
| **11:20-12:00** | **2- Deerland Enzymes & Probiotics**  Title: Next Generation Prebiotic Technology  Abstract: Evidence has been mounting showing the value of prebiotics in supporting the structure and function of the microbiota, and the concept of synbiosis has been shown by researchers to be effective in creating, restoring and sustaining that beneficial balance. The scientists at Deerland have developed a unique prebiotic bacteriophage blend that modulates the microbiota and begins to work within hours after ingestion. Dr. John Deaton will present the findings of a recently published clinical study which shows that the phage cocktail of PreforPro® supports gut microbiota proliferation and reduces other biochemical markers, strengthening the body of evidence to make a claim of symbiotic efficacy, and to promote growth of good bacteria. This presentation will highlight the athlete-specific benefits of *Bacillus subtilis* DE111® with support from the results of two clinical studies.  Topics  • The evolving market for prebiotics and the innovative mechanisms of action beyond traditional fibers and starches  • Clinical results demonstrating how a bacteriophage cocktail modulates the microbiome without disrupting global microbiota, and the systemic effects that result when beneficial bacterial species are able to proliferate  Presenter: Dr John Deaton, Ph.D.  Job Title: Vice President of Science and Technology, Deerland Probiotics & Enzymes  Bio: Dr. Deaton holds more than 20 years’ experience working with proteins and enzymes. He holds a PhD in biochemistry from Texas A&M University, with post-graduate studies in microbiology, biophysics and cancer research. He has two papers published in the Proceedings of the National Academy of Sciences (PNAS) and is an eleven-year member of the Association of Official Analytical Chemists (AOAC), with four years served on the committee of microbiology.  Company Profile: Deerland Probiotics & Enzymes, based in Kennesaw, Ga., specializes in developing science-backed solutions that benefit microbiome health, using probiotic, prebiotic and enzyme technology. The company offers a line of unique, clinically supported branded products, including DE111®, PreforPro®, ProHydrolase®, Solarplast® and Glutalytic®. Deerland collaborates with customers to develop innovative and often proprietary solutions in the dietary supplement and food and beverage markets. In addition to branded ingredients and customized formulations, Deerland offers full turn key manufacturing services, including bulk blends, capsules, stick packs and tablets; as well as bottling and labeling. To contact Deerland Probiotics & Enzymes, call 800.697.8179 or visit [www.deerland.com](http://www.deerland.com). | **10- Ashland**  Title: Immune Boosting Probiotics  Abstract: Your body contains billions of immune cells that are part of your body's natural defenses. The stress of your busy life can take a toll on your immune system. Your gut and your immune system are very closely linked, with 70 to 80 percent of your immune tissue being situated in your digestive tract. Rebalancing the gut microbiome with specific probiotic strains can boost your immune system, helping to maintain health and wellness.  Topics   * Beauty from within: oral skin care probiotics * The role of probiotics in food allergies * Can probiotics help people with asthma?     Presenter: Dr. Ralf Jäger, FISSN, CISSN, MBA, Increnovo LLC  Job Title: Senior Scientific Advisor to Ashland  Bio: Dr. Ralf Jäger is an award-winning speaker on functional foods and dietary supplements. He has authored and published numerous peer-reviewed scientific papers, industry publications and mainstream media articles on gut, brain, joint, and heart health, and is a leading expert in the field of probiotics. A postdoctoral scholar in bio-organic chemistry at the California Institute of Technology (Caltech) in Pasadena, California, Dr. Jäger originally earned his Ph.D. in organic chemistry from the University of Bonn in Germany. He is a Fellow of the International Society of Sports Nutrition (FISSN) and is currently a member of numerous scientific associations, including, most notably, the American Gastroenterological Association (AGA).  Company Profile: Ashland company profile (booth 4049)  At **Ashland**, we are **passionate, tenacious, solvers** who thrive on developing practical, innovative and elegant solutions to complex problems, always pushing the boundaries of what’s possible, to advance the competitiveness of our customers. No one knows more or cares more about how to transform the **efficacy**, **usability**, **allure**, **integrity** and **profitability** of nutraceutical products and applications. We pride ourselves in bringing a broad range of specialty solutions to everyday health and wellness products. Our capabilities include proprietary ingredients, custom formulation and particle engineering. We are always solving™. |
| **12:00-12:10** | **Break** | **Break** |
| **12:10-12:50** | **3- Kerry**  Title: Identifying the Global Whitespace for Probiotic Products  Abstract: Consumers are demanding the addition of probiotics into everyday foods and beverages. Today you can find them in everything from snacks and juices to meal replacements and oatmeal. However, there are some categories where consumers can’t find probiotic benefits in the foods they love. In this session we’ll go through some of those categories, present the opportunity available in the probiotic food and beverage space and show why doing your research on the strain is important.  Topics  • The growth areas in the probiotic food and beverage space.  • The benefits of doing your research when searching for a probiotic strain.  • The science behind digestive and immune benefits.    Presenter: Dr Don Cox, PhD  Job Title: R&D Director – Kerry ProActive Health  Bio: Dr. Cox leads R&D efforts for Kerry's portfolio of branded science-backed nutritional ingredients. Areas of responsibility include clinical research, regulatory filings, product development and technical services. Don has significant experience with the commercialization of natural products in the industry. Don has worked exclusively in the natural products industry during his career. He has held positions with Biothera, DKSH North America, Cargill and Diamond V. Dr. Cox has a Ph.D. in Food Microbiology from Cornell University and an MBA from the University of Iowa.  Company Profile: Kerry is fueling innovation through taste, nutrition and functionality. The company’s portfolio of better-for-you solutions solves the challenges of creating products with the benefits consumers seek. Ganeden**BC30®** (*Bacillus coagulans* GBI-30, 6086), a Kerry brand, is a is a patented, FDA GRAS probiotic ingredient found in more than 1000 leading food and beverage products around the world. It is a shelf-stable, science-backed probiotic strain that has been shown to provide digestive health, immune health and protein utilization benefits. Highly stable, Ganeden**BC30** remains viable throughout most manufacturing processes and the low pH of stomach acid. Well-researched and easy to formulate into functional food, beverages and companion animal products, Ganeden**BC30** is backed by over 25 published papers. Part of Kerry’s nutrition and wellness portfolio, Ganeden**BC30** is natural, vegan, Non-GMO Project verified, organic compliant and allergen-free. For more information, please visit: Ganedenprobiotics.com. | **11- Unique Biotech**  Title: The effects of probiotic supplement, *Bacillus coagulans* Unique IS2 on protein absorption in resistance trained adult males  Abstract: In this double blind, placebo-controlled study, sixty resistance trained males aged between 18-25 years following a controlled exercise protocol were randomized to consume either 20 g of whey protein containing probiotic *Bacillus coagulans* Unique IS2 (2 billion cfu) or Whey protein alone for 60 days. It was observed that *Bacillus coagulans* Unique IS2 enhanced the absorption of whey protein and its utilization with a significant increase in the serum levels of branched chain amino acids, leucine, isoleucine and valine.  Topics  • Absorption of branched chain amino acids leucine, isoleucine, and valine after whey protein supplementation.  • Absorption of other amino acids such as Aspartic acid, Glutamic acid, Serine, Threonine, Tyrosine, Methionine and hydroxyproline were increased.  • Muscular strength and power as evidenced by Repetition Maximum (RM) of leg press and vertical jump.  Presenter: Dr Jayanthi Neelamraju, Ph.D.  Job Title: Manager- Scientific Affairs, Unique Biotech Ltd  Bio: Dr. Jayanthi holds a PhD degree in Biochemistry from the National Institute of Nutrition, Hyderabad, India and is a registered patent agent with the Government of India. She has published in peer reviewed journals in areas related to Nutrition and carcinogenesis apart from probiotics. At Unique Biotech Ltd, she is involved in Scientific liaising with various universities, research institutes and hospitals for collaborative research on probiotics  Company Profile: Unique Biotech Ltd (UBL) is a world class, dedicated and a well laid out large scale fermentation facility established in 2001 for Probiotics, Enzymes, and Nutraceuticals with state-of-the-art equipment in Genome Valley, Hyderabad, India. It is totally committed to the discovery, development and commercialization of innovative formulations for improved health care at affordable cost. UBL has dedicated blocks for production of Bacillus sp, Lactobacillus sp, Bifidobacterium sp and Saccharomyces *boulardii*. Unique Biotech is an ISO 9001:2015 and a WHO-GMP certified company constantly innovating to provide disease specific. |
| **12:50-1:00** | **Break** | **Break** |
| **1:00-1:40** | **4- UAS Labs**  Title: Clinical Research, Changing the Probiotic Landscape  Abstract: As consumer awareness and interest around the probiotic space continues to grow, probiotic manufacturers must focus on clinical research to support their offerings. UAS Labs has been investing in clinical research for over 40 years and just recently completed one of the largest ever probiotic IBS studies! Join Dr. Greg Leyer as he shares, for the very first time, the results from a study which assessed the effect of probiotics on symptomology in over 300 subjects with IBS.  Topics  • Clinical research and its importance within the probiotic space.  • Outcomes measured in studies evaluating IBS symptoms.  • Results from UAS Labs’ most recent clinical study involving >300 adults with IBS.    Presenter: Dr. Gregory Leyer, Ph.D.  Job Title: Chief Scientific Officer  Bio: Dr. Greg Leyer has dedicated his professional career to probiotic advancement making him not only a critical component of UAS Labs but a world-renowned expert, educator and speaker in the field. To continue driving the industry and UAS Labs forward, Dr. Greg continues research in the areas of probiotic bioprocess development, application development, and clinical sciences. To-date he has authored or co-authored 24 publications in the areas of probiotic clinical results, application know-how, safety parameters, and holds patents in the field. In addition, he is an active member of both the International Probiotic Association (IPA) and International Scientific Association for Probiotics and Prebiotics (ISAPP). A graduate of the University of Wisconsin-Madison, Dr. Greg received his M.S and Ph.D. in Food Microbiology and Toxicology studying the pathogenesis of various organisms including *Clostridium botulinum* and *Salmonella typhimurium*. His post-graduate career has since focused on the beneficial effects microbes have on humans.  Company Profile: UAS LABS Is focused on one thing and one thing only, delivering the best probiotic based solutions. It's all we do, it's all we've ever done.  Since 1979 our probiotic strains and finished formulations have been backed by tireless research and rigorous clinical trials. From strain to solution, every manufacturing step is meticulously performed to maintain product viability and to ultimately deliver a health benefit to the end-consumer. UAS Labs is proud to be one of the few probiotic contract manufacturing companies in the world to provide a fully-integrated production process. It’s easy to see how we’ve earned our name as *The Probiotic Company®*. | **12- Nutrasource Pharmaceutical &**  **Nutraceutical Services**  Title: Using Data Science to Drive Innovation in the Probiotics Industry  Abstract: Using data science platforms to accurately capture and pool product information for integration into product innovation is a novel concept for the probiotic industry. This talk will focus on how companies may aggregate their often-siloed marketing, safety and efficacy data in a standardized fashion to optimize claims potential of existing SKU’s as well as provide key feedback information to the new product development and innovation cycle.  Topics  • How to effectively pool scientific data.  • The importance of aggregating information to optimize claims.  • Provide key feedback information for new product development.  Presenter: Joshua Baisley, H.B.Sc.  Job Title: Vice President of Clinical Design and Delivery  Bio: Joshua joined Nutrasource in 2013, bringing over 12 years of quality assurance, clinical, preclinical and regulatory natural health product experience and an additional four years of antibody/biologics development experience. Having depth in both regulatory filings and project management of clinical trials provides Josh with an understanding of regulatory body thinking and has led to his respected relationship with Health Canada. Josh has a Hons. B.Sc. from the University of Guelph, specializing in microbiology and certificates in regulatory affairs and clinical trial project management.  Company Profile: Nutrasource Pharmaceutical and Nutraceutical Services is a full-service contract research organization (CRO) that helps health companies bring products to market with strong science and regulatory confidence. As your virtual R&D department, we will help you tackle your toughest scientific problems so you can sell safe, effective, high-quality products to improve healthcare globally. |
| **1:40-1:50** | **Break** | **Break** |
| **1:50-2:30** | **5- SynbioTech**  Title: SYNKEFIR™ ─ New innovation in Postbiotics for functional foods  Abstract: Postbiotics is an emerging field of research with exciting potential to the use of bioactive compounds, including non-viable bacteria and its metabolites produced by good bacteria, with physiological benefits to the host. The recent studies indicate that probiotic metabolites or its cell lysates could be key regulators of gastrointestinal (GI) health and help maintain intestinal homeostasis. SynbioTech’s latest product, SYNKEFIR™, is a non-living microbial cell product, collected from the culture supernatant of 5 symbiotic Kefir strains by unique SYNTEK™ thorough process. SYNKEFIR is suitable for diverse applications in functional food and beverage, nutraceuticals, and sport nutrition thanks to its healthy proven properties.  Topics   * Kefir: one of oldest probiotics with health-promoting benefits * The important role of bacterial metabolites in the human gut * An emerging field of research and application in functional foods and sport nutrition   Presenter: Wen-Shiaw Lan  Job Title: Overseas Affairs Manager  Bio: My field of interest is related to food science and biotechnology, and I believe the biotechnology industry will be one of the most powerful industries in the future. After received master degrees in food science major at National Chung-Hsing University in Taiwan and biotechnology major at Texas A&M University including intern at the Southern Plains Agricultural Research Center of USDA, I was working for SYNBIO TECH Inc. as a researcher in R&D center for probiotic and starter culture project, and now serving as a manager for marketing and promotion of commercial probiotics in overseas market for more than 10 years. The oversea business partners are from worldwide including Americas, EU, South East Asia, Pacific Asia, Middle East, etc.  Company Profile: SYNBIO TECH INC. is one of largest microbiome-based probiotic manufacturer in Asia, offering high potency, sustained stability, and health-enhancing probiotic strains and formulations. These include SYNKEFIR™, a new innovation in postbiotics and beneficial for exercise performance, anti-fatigue, and muscular endurance. | **13- Fluid Air**  Title: Processing Probiotics  Abstract: The process of Electrostatic Spray Drying delivers higher quality microencapsulated products that have increased potency, stability, longer shelf-life and provides superior dissolution. Electrostatic technology drives the water or solvent to the shell and the active to the core, lowering the required evaporation temperature and eliminating active ingredient loss, degradation or denaturalization. Harnessing the electrostatic effect, the dispersed active is driven into the core is microencapsulated, virtually eliminating surface active, resulting in stunning encapsulation efficiency.  Topics  • Microencapsulation  • Electrostatic  • Temperature Sensitive Materials  Presenter: Robert Sakhnovsky  Job Title: Product Specialist, Fluid Air  Bio: Robert Sakhnovsky is the Midwest Product Specialist for Fluid Air, a Division of Spraying Systems Co. Robert, an engineering graduate of Purdue University, joined the Fluid Air PolarDry team in its early beginnings. His responsibilities include mentoring and coordination with the sales team for the development of new product applications and consulting customers over product development including oral solid dosage, bulk powder production, oil powder microencapsulation, and commercial bacteria manufacturing. He has given technical discussions, product demonstrations, and provided worldwide sales and technical expertise support. For over 30 years, Fluid Air has provided the highest quality equipment to the food and pharmaceutical industries and he is proud to continue that tradition.  Company Profile: Fluid Air specializes in developing equipment for the modification/creation of powders and particles & providing customized solutions to solid dosage process challenges across industries including pharmaceuticals, foods, & probiotics. Through a combination of core-shell microencapsulation and the electrostatic effect utilized in our PolarDry® Electrostatic Spray Dry Systems, we can provide greater encapsulation efficiency, superior morphology, and longer shelf-life which will eliminate the need for traditional and/or secondary agglomeration operations. As a result, Fluid Air has emerged as a leader in the global process community with well-established reputation for best-in-class service. |
| **2:30-2:40** | **Break** | **Break** |
| **2:40-3:20** | **6- ROELMI HPC**  Title: SynBalance® probiotic complex against metabolic syndrome. A potentially new ally in the public health preventive approach to metabolic and cardiovascular risk?  Abstract: A probiotic formula containing *Lactobacillus plantarum* PBS067, *Lactobacillus acidophilus* PBS066 and *Lactobacillus reuteri* PBS072 was tested in a RDBPC clinical trial, enrolling 60 patients with metabolic syndrome. After 14 days of run-in, the probiotic and placebo supplements were administered for 2 months. Patients were evaluated by physical, laboratory, haemodynamic analyses and by Quality of Life (EQ-5D) questionnaire at T0 and T60. Patients receiving the active treatment experienced a statistically significant improvement in anthropometric measures, in lipid and glycaemic levels, in chronic inflammation markers and for perceived quality of life, compared both to baseline and placebo.  Topics  • Reduction of metabolic syndrome prevalence and cardiovascular risk factors.  • Improvement of markers of insulin resistance and self-perceived healthy status.  • Decreased markers of systemic inflammation.  Presenter: Dr Cristiana Piangiolino, Ph.D.  Job Title: Marketing Manager, Nutraceutical & Food, ROELMI HPC  Bio: Cristiana Piangiolino is the Market Manager for Nutraceuticals and Food in ROELMI HPC. She is in charge of planning medium-long term strategies by looking at worldwide market trends. Thanks to the acquired know-how in the fermentation processes, Cristiana is also Product Manager for Biotechnology product lines such as SynBalance® Probiotics and full spectrum ExceptionHYAL® Hyaluronans. After an initial practise as Nutraceutical Sales Manager for the Italian market, she gradually gained experience developing business in other European countries. Cristiana Piangiolino joined Principium Europe in 2010, where she helped build the strong company reputation as supplier of active ingredients, thanks to her technical background and international expertise. From end of 2016, she contributed to the smooth transition of Principium brands into ROELMI HPC portfolio, after a merge by incorporation. Graduated in Chemistry at Milan University with a short scholarship in Valencia - Spain, Cristiana Piangiolino finalized her PhD thesis in 2007, at Paris VI University – France about “Organometallic enantioselective catalysis for the synthesis of pharmaceutical intermediates”.  Company Profile: ROELMI HPC is now the global expert for actives and functionals in Health & Personal Care. But its roots date back to 1946 in the Mediterranean area, where the company still finds concepts and innovation-driven technologies, in full respect of nature and people. Its products are developed thanks to avant-garde research, scientific approach and true passion. From its Biotech research: ExceptionHYAL®, 2.0 generation of full-spectrum Hyaluronans and SynBalance®, life-wide proprietary probiotics. From its Nature preservation commitment: SelectSIEVE®, Mediterranean matrixes for real circular economy and Beaulixir®, specific system to support the healthy hair physiology. | **14 – International Probiotics Association**  Title: Understanding the U.S. Probiotic User – An IPA Perspective  Abstract: With all the reports about probiotic market growth in the US slowing down, the industry is trying to understand what all this means. Like any market correction, all this means is there is an opportunity for the industry to become stronger on product innovation and science.  Topics  • How new entrants cannibalize a market.  • Education can go a long way in product development and sales.  • And quality always wins over price every time.  Presenter: George Paraskevakos, MBA  Job Title: Executive Director, International Probiotics Association  Bio: George has been involved with the probiotic industry since 2007 where he served in various roles from business development to account management with a globally recognized probiotic producer. During this time, he also served on the IPA Board of Directors (BoD) and had two (2) mandates as President before taking on the association’s leadership role as Executive Director in 2015. His passion for the probiotic industry is unequivocal and his persistence to have IPA continue being **The Global Voice of Probiotics®** has taken the association from 40 members when he took on the role to now over 100 international companies under his tutelage. George represents the International Probiotics Association in the media, to all probiotic industry stakeholders including government agencies and Codex, and in appearances at conventions, conferences, and other symposiums.  Company Profile: The International Probiotics Association (IPA) is a global non-profit organization bringing together through its membership, the probiotic sector’s stakeholders including but not limited to academia, scientists, health care professionals, consumers, industry and regulators. The IPA’s mission is to promote the safe and efficacious use of probiotics throughout the world. Holding NGO status before Codex Alimentarius, the IPA is also recognized as the unified Global Voice of Probiotics® around the world. |
| **3:20-3:30** | **Break** | **Break** |
| **3:30-4:10** | **7- Lallemand Health Solutions**  Title: ComboCap®’Biotics by Lallemand  Abstract: ComboCap®’Biotics, is an innovative solution to housing unprocessed, incompatible probiotic ingredients in a single capsule. This new side-by-side capsule allows each component to retain their identity and efficacy allowing the creation of new brand categories in combination supplements.  Topics  • Presentation of the technology  • Features and Benefits  • Examples of possible formulas and possible claims  Presenter: Bérengère Feuz  Job Title: Marketing Director, Lallemand Health Solutions  Bio: Bérengère Feuz is graduated from HEC Paris and has worked for the pharmaceutical and nutraceutical industry for eighteen years as a consultant and product manager. For the last ten years, she has worked at Lallemand Health Solutions, heading the global marketing department, and striving to bring evidence-based innovative and effective probiotic solutions to the market.  Company Profile: Backed by a rich history and 80 years of expertise in probiotic research and development, Lallemand Health Solutions offers a full line of ready-to-market probiotic formulas and helps its partners to design their own custom & complex formulations using Harmonium, LAFTI® or Rosell® Probiotic strains together with our proprietary protective technologies. Because, from the lab to the shelf, Lallemand Health Solutions controls the overall manufacturing process of its products, the company can ensure customers are receiving the highest quality standard of probiotic formulation. Cooperation spells success: we provide our partners with the full support they need to develop, register, and market their products in their own market, making Lallemand Health Solutions a complete probiotic solutions provider. Lallemand Health Solutions covers more than 60 countries across five continents and is ready to service your probiotic needs. For more information, please visit www.lallemand-health-solutions.com |  |
| **4:10-4:20** | **Break** | **Break** |
| **4:20-5:00** | **8- Eurofins**  Title: Probiotic Product Development – Considerations, Challenges, and Evaluation for Market Acceptance and Quality  Abstract: The public is taking note of probiotics and with this there are many ideas of the next probiotic product -- but how do you formulate and verify a new probiotic product correctly? Probiotics are living organisms that you want to keep alive through the end of shelf-life and include in exciting and complex mixtures and with other ingredients. In this presentation we will take you through the development, evaluation, and stability of three different probiotic finished products including a single strain and a blend of different organisms. The presentation will define considerations and technologies and methods to use through ingredient selection, evaluation of delivery vehicles, applications for encapsulation, how to formulate correctly and without excess overage, and also how to ensure shelf-life, stability, and label claims.  Topics  • Ingredient Selection and Evaluation as Single Strains vs. Blends.  • Formulation in Pilot and Scale-up.  • Label Creation and Evaluation.  Presenter: Mehgan Styke  Job Title: Business Development Director, Eurofins  Bio: Mehgan Styke is the National Business Development Director, specializing in microbial-based products and sequencing services for Eurofins Scientific Inc. and Eurofins BioDiagnostics. For over 10 years, Mehgan has lead teams in business and laboratory excellence with constant evaluation of relevant and evolving microbial and molecular methods/technologies and industry product trends. Mehgan’s passion is to support the probiotic and natural product industries with focus and expertise on genomic technologies, and an acute awareness of the compliance needs and challenges when using live and natural ingredients in the food, feed, and supplement industries.  Company Profile: Eurofins Scientific is your probiotic expert. We offer probiotic cultural enumerations, molecular assays, identification services of strains and blended products, flow- cytometry stability study, and product development support, in addition to our complimentary analytical methods. Come stop by our booth #6571 to discuss how we can support your probiotic products! | **16- IPA & Amin Talati Wasserman**  Title: IPA Comedy Show featuring Ivan Wasserman  Abstract: In what has become a Probiotic Resource Center tradition, Ivan Wasserman closes out the show with his one-of-a-kind probiotic comedy revue! You may laugh. You may cry. Either way it promises to be unforgettably regrettable.  Topics  • See the world’s only “**Probiotic Comic**” in action  • You will laugh.  • You will cringe.  • You will make fun of Ivan.  Presenter: Ivan Wasserman, Esq.  Job Title: Legal Professional - Amateur Comedian; IPA Legal Counsel & Managing Partner, Amin Talati Wasserman  Bio: Ivan Wasserman is the Managing Partner of the law firm Amin Talati Wasserman LLP. Noted for expertise in foods, dietary supplement, and cosmetics, Ivan and his team represent clients before the FDA, the FTC, the CPSC, State Attorneys General, and in class action litigation. Ivan also serves as counsel to the International Probiotics Association, is a frequent speaker and author on regulatory issues, and has been included in Best Lawyers (and worst comedians) in America from 2007 to 2019.  Company Profile: Amin Talati Wasserman LLP is one of the nation's leading regulatory and intellectual property law firms with offices in Chicago and Washington, D.C. The firm represents a sophisticated client base — including Fortune 500, middle-market and emerging companies — in the food, dietary supplement, pharmaceutical, cosmetic and medical device industries. |
|  | **Closing** | **Closing** |
| *All times are in Pacific Time zone* | |  |